EUVIMEDObjevte EUVIMED
Crossref

Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes

Bade Gulec iD, Elif Everest, Ogeday Derin Gorkey, Metehan Koc, Melih Tutuncu, Sabahattin Saip, Aksel Siva, Ugur Uygunoglu

European Journal of Neurology · 2023

DOI: 10.1111/ene.15913 ↗

At a glance

Journal article in European Journal of Neurology, 2023. Written by Bade Gulec and 7 co-authors. Institution: Department of Neurology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Major MEDLINE topics: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive. Cited 5 times so far (Crossref); 31 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Patients with multiple sclerosis (MS) who discontinue fingolimod might present with rebound activity. The reasons for the development of rebound have been identified, but there are limited data on the long‐term clinical outcomes of these patients. This study aimed to compare the long‐term outcomes of patients with MS with and without rebound activity after fingolimod discontinuation.

Methods

A total of 31 patients who discontinued fingolimod for various reasons with a minimum follow‐up of 5 years were included in the study. Of these, 10 were assigned to the rebound group and 21 to the non‐rebound group. Clinical and demographic data and 5‐year clinical outcomes of both groups were prospectively examined.

Results

At fingolimod initiation, there were no significant differences in age, disease duration, and Expanded Disability Status Scale (EDSS) score. The annualized relapse rate (ARR) was significantly higher in the rebound group than in the non‐rebound group before the fingolimod treatment ( p = 0.005). In the rebound group, EDSS scores 2 months after rebound treatment and at the 5‐year follow‐up were not significantly different than before fingolimod initiation ( p = 0.14 and p = 0.46, respectively). The last recorded EDSS was significantly higher in the non‐rebound group than in the rebound group (3.6 ± 2.3 vs. 2.15 ± 1.4, p = 0.045). At the last follow‐up, one patient was diagnosed with secondary progressive multiple sclerosis in the rebound group (10%), and 11 patients were in the non‐rebound group (52.4%, p = 0.05).

Conclusion

When rebound activity is well‐monitored and treated after fingolimod discontinuation, no overall EDSS change is expected in the long‐term follow‐up.

Subjects

MeSH terms (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveHumansFingolimod HydrochlorideRecurrenceImmunosuppressive Agents

Author keywords

annualized relapse rateclinical outcomefingolimod cessationfingolimod reboundmultiple sclerosis

Substances

Fingolimod HydrochlorideImmunosuppressive Agents

Authors and institutions

  • Department of Neurology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

ORCID profiles: Bade Gulec

Cite

APA

Gulec, B., Everest, E., Gorkey, O. D., Koc, M., Tutuncu, M., Saip, S., Siva, A., & Uygunoglu, U. (2023). Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes. European Journal of Neurology. https://doi.org/10.1111/ene.15913

Vancouver

Gulec B, Everest E, Gorkey OD, Koc M, Tutuncu M, Saip S, et al. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes. European Journal of Neurology. 2023. doi:10.1111/ene.15913

BibTeX
@article{Gulec2023,
  author = {Gulec, Bade and Everest, Elif and Gorkey, Ogeday Derin and Koc, Metehan and Tutuncu, Melih and Saip, Sabahattin and Siva, Aksel and Uygunoglu, Ugur},
  title = {Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15913}
}
Start for free →